Malaysia · Delayed Price · Currency is MYR Pharmaniaga Berhad Statistics
Total Valuation
KLSE:PHARMA has a market cap or net worth of MYR 1.52 billion. The enterprise value is 2.17 billion.
| Market Cap | 1.52B |
| Enterprise Value | 2.17B |
Important Dates
The next estimated earnings date is Friday, November 27, 2026.
| Earnings Date | Nov 27, 2026 |
| Ex-Dividend Date | Sep 14, 2026 |
Share Statistics
KLSE:PHARMA has 1.31 billion shares outstanding. The number of shares has increased by 328.22% in one year.
| Current Share Class | 1.31B |
| Shares Outstanding | 1.31B |
| Shares Change (YoY) | +328.22% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 6.34% |
| Owned by Institutions (%) | 13.47% |
| Float | 346.92M |
Valuation Ratios
The trailing PE ratio is 24.36 and the forward PE ratio is 6.26.
| PE Ratio | 24.36 |
| Forward PE | 6.26 |
| PS Ratio | 0.37 |
| PB Ratio | 3.15 |
| P/TBV Ratio | 4.12 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 36.89 |
| EV / Sales | 0.52 |
| EV / EBITDA | 13.76 |
| EV / EBIT | 17.18 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.01, with a Debt / Equity ratio of 1.62.
| Current Ratio | 1.01 |
| Quick Ratio | 0.55 |
| Debt / Equity | 1.62 |
| Debt / EBITDA | 4.94 |
| Debt / FCF | -5.36 |
| Interest Coverage | 2.69 |
Financial Efficiency
Return on equity (ROE) is 33.70% and return on invested capital (ROIC) is 8.28%.
| Return on Equity (ROE) | 33.70% |
| Return on Assets (ROA) | 3.41% |
| Return on Invested Capital (ROIC) | 8.28% |
| Return on Capital Employed (ROCE) | 14.87% |
| Weighted Average Cost of Capital (WACC) | 6.72% |
| Revenue Per Employee | 1.19M |
| Profits Per Employee | 16,829 |
| Employee Count | 3,502 |
| Asset Turnover | 1.80 |
| Inventory Turnover | 5.48 |
Taxes
In the past 12 months, KLSE:PHARMA has paid 24.58 million in taxes.
| Income Tax | 24.58M |
| Effective Tax Rate | 28.58% |
Stock Price Statistics
The stock price has increased by +32.57% in the last 52 weeks. The beta is 0.67, so KLSE:PHARMA's price volatility has been lower than the market average.
| Beta (5Y) | 0.67 |
| 52-Week Price Change | +32.57% |
| 50-Day Moving Average | 1.19 |
| 200-Day Moving Average | 1.28 |
| Relative Strength Index (RSI) | 41.85 |
| Average Volume (20 Days) | 2,950,505 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KLSE:PHARMA had revenue of MYR 4.17 billion and earned 58.94 million in profits. Earnings per share was 0.05.
| Revenue | 4.17B |
| Gross Profit | 422.82M |
| Operating Income | 126.57M |
| Pretax Income | 86.02M |
| Net Income | 58.94M |
| EBITDA | 147.41M |
| EBIT | 126.57M |
| Earnings Per Share (EPS) | 0.05 |
Balance Sheet
The company has 152.31 million in cash and 780.91 million in debt, with a net cash position of -628.60 million or -0.48 per share.
| Cash & Cash Equivalents | 152.31M |
| Total Debt | 780.91M |
| Net Cash | -628.60M |
| Net Cash Per Share | -0.48 |
| Equity (Book Value) | 482.89M |
| Book Value Per Share | 0.35 |
| Working Capital | 15.98M |
Cash Flow
In the last 12 months, operating cash flow was -51.10 million and capital expenditures -94.56 million, giving a free cash flow of -145.66 million.
| Operating Cash Flow | -51.10M |
| Capital Expenditures | -94.56M |
| Depreciation & Amortization | 20.83M |
| Net Borrowing | -361.30M |
| Free Cash Flow | -145.66M |
| FCF Per Share | -0.11 |
Margins
Gross margin is 10.15%, with operating and profit margins of 3.04% and 1.41%.
| Gross Margin | 10.15% |
| Operating Margin | 3.04% |
| Pretax Margin | 2.07% |
| Profit Margin | 1.41% |
| EBITDA Margin | 3.54% |
| EBIT Margin | 3.04% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.02, which amounts to a dividend yield of 1.45%.
| Dividend Per Share | 0.02 |
| Dividend Yield | 1.45% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 2 |
| Payout Ratio | n/a |
| Buyback Yield | -328.22% |
| Shareholder Yield | -326.76% |
| Earnings Yield | 3.87% |
| FCF Yield | -9.58% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for KLSE:PHARMA is 1.53, which is 31.90% higher than the current price. The consensus rating is "Buy".
| Price Target | 1.53 |
| Price Target Difference | 31.90% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 4.65% |
| EPS Growth Forecast (3Y) | 79.89% |
Stock Splits
The last stock split was on June 8, 2026. It was a reverse split with a ratio of 0.2.
| Last Split Date | Jun 8, 2026 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
KLSE:PHARMA has an Altman Z-Score of 2.38 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.38 |
| Piotroski F-Score | 3 |